File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Outcome of Haematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukaemia in Hong Kong

TitleOutcome of Haematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukaemia in Hong Kong
Authors
Issue Date2013
PublisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp
Citation
Joint Annual Scientific Meeting 2013 of The Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association, Hong Kong, 8 September 2013. In Hong Kong Journal of Paediatrics (New series), 2013, v. 18 n. 4, p. 243 How to Cite?
AbstractPurpose: We aimed to review the outcomes of children with acute myeloid leukaemia (AML) who received allogeneic haematopoietic stem cell transplant (HSCT) in Queen Mary Hospital. Methods: We performed a retrospective review of all children with AML who underwent allogeneic HSCT in the past 20 years (1994-2013) and analysed their transplant outcomes. Results: We have performed allogeneic HSCT for 45 children (29 boys and 16 girls) with AML. The median age at HSCT was 9.1 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission (CR1), 20 in second remission (CR2), 1 in third remission (CR3), and 8 with non-remission (NR). Donors were matched sibling (MS) (n=19), 1-antigen mismatched parent (MP) (n=2), matched unrelated donor (MUD) (n=11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (single CB: n=10, double CB: n=3). Five-year overall survival (OS) and relapse-free survival (RFS) were 42.7% and 33.6% respectively. Survivals differed significantly with remission status (OS: 55% in CR1, 44.6% in CR2, vs. 14.3% in CR3/ NR; RFS: 55% in CR1, 24.2% in CR2, vs. 14.3% in CR3/ NR). OS but not RFS was significantly better in patients who received UCB compared to MS, MUD, or MP (OS: 68.7% vs. 34.4% vs. 36.4% vs. 0%). OS and RFS were 100% for patients with double cord blood transplant but the followup was short (median 9 months). Transplant-related mortalities in UCB, MS, MUD, and MP were 7.7%, 17.6%, 72.7% and 50% respectively. Conclusion: Mortality remains high in children with AML despite stem cell transplantation. Outcomes were better for patients transplanted in first complete remission and those who received unrelated cord blood, especially double cord blood.
DescriptionPoster Presentation (Doctor’s Session)
Persistent Identifierhttp://hdl.handle.net/10722/190129
ISSN
2015 Impact Factor: 0.194
2015 SCImago Journal Rankings: 0.123

 

DC FieldValueLanguage
dc.contributor.authorCheuk, KLDen_US
dc.contributor.authorChiang, AKSen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorChan, GCFen_US
dc.date.accessioned2013-09-17T15:12:07Z-
dc.date.available2013-09-17T15:12:07Z-
dc.date.issued2013en_US
dc.identifier.citationJoint Annual Scientific Meeting 2013 of The Hong Kong Paediatric Society and Hong Kong Paediatric Nurses Association, Hong Kong, 8 September 2013. In Hong Kong Journal of Paediatrics (New series), 2013, v. 18 n. 4, p. 243en_US
dc.identifier.issn1013-9923-
dc.identifier.urihttp://hdl.handle.net/10722/190129-
dc.descriptionPoster Presentation (Doctor’s Session)-
dc.description.abstractPurpose: We aimed to review the outcomes of children with acute myeloid leukaemia (AML) who received allogeneic haematopoietic stem cell transplant (HSCT) in Queen Mary Hospital. Methods: We performed a retrospective review of all children with AML who underwent allogeneic HSCT in the past 20 years (1994-2013) and analysed their transplant outcomes. Results: We have performed allogeneic HSCT for 45 children (29 boys and 16 girls) with AML. The median age at HSCT was 9.1 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission (CR1), 20 in second remission (CR2), 1 in third remission (CR3), and 8 with non-remission (NR). Donors were matched sibling (MS) (n=19), 1-antigen mismatched parent (MP) (n=2), matched unrelated donor (MUD) (n=11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (single CB: n=10, double CB: n=3). Five-year overall survival (OS) and relapse-free survival (RFS) were 42.7% and 33.6% respectively. Survivals differed significantly with remission status (OS: 55% in CR1, 44.6% in CR2, vs. 14.3% in CR3/ NR; RFS: 55% in CR1, 24.2% in CR2, vs. 14.3% in CR3/ NR). OS but not RFS was significantly better in patients who received UCB compared to MS, MUD, or MP (OS: 68.7% vs. 34.4% vs. 36.4% vs. 0%). OS and RFS were 100% for patients with double cord blood transplant but the followup was short (median 9 months). Transplant-related mortalities in UCB, MS, MUD, and MP were 7.7%, 17.6%, 72.7% and 50% respectively. Conclusion: Mortality remains high in children with AML despite stem cell transplantation. Outcomes were better for patients transplanted in first complete remission and those who received unrelated cord blood, especially double cord blood.-
dc.languageengen_US
dc.publisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp-
dc.relation.ispartofHong Kong Journal of Paediatrics (New series)en_US
dc.titleOutcome of Haematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukaemia in Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheuk, KLD: klcheuk@hkucc.hku.hken_US
dc.identifier.emailChiang, AKS: chiangak@hku.hken_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChan, GCF: gcfchan@hku.hken_US
dc.identifier.authorityChiang, AKS=rp00403en_US
dc.identifier.authorityChan, GCF=rp00431en_US
dc.description.naturelink_to_OA_fulltext-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros225083en_US
dc.identifier.volume18-
dc.identifier.issue4-
dc.identifier.spage243en_US
dc.identifier.epage243en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats